Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3

American Journal of Pathology

Volumn 176, Issue 4, 2010, Pages 1756-1766

  Migita, Toshiro ^a,d   Narita, Tadahito ^a,b   Asaka, Reimi ^a   Miyagi, Erika ^a   Nagano, Hiroko ^a   Nomura, Kimie ^a   Matsuura, Masaaki ^a,c   Satoh, Yukitoshi ^d   Okumura, Sakae ^d   Nakagawa, Ken ^d   Seimiya, Hiroyuki ^d   Ishikawa, Yuichi ^a  

^a CANCER INSTITUTE   (Japan)

^b ZENYAKU KOGYO CO LTD   (Japan)

^c Genome Center   (Japan)

^d CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BIOLOGICAL MARKER; CAMPTOTHECIN; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; PROCASPASE 3; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CLINICAL ASSESSMENT; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SENSITIZATION;

EID: 77950586562     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090500     Document Type: Article

References (66)

1. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J, Price JT: Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 2004, 64:977-984 (Pubitemid 38176900)
2. Wang GK, Hu L, Fuller GN, Zhang W: An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 2006, 281:14085-14091 (Pubitemid 43848335)
3. Russo VC, Bach LA, Fosang AJ, Baker NL, Werther GA: Insulin-like growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 1997, 138:4858-4867
4. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW: Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004, 32:859-868 (Pubitemid 38877689)
5. Firth SM, Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002, 23:824-854 (Pubitemid 35454590)
6. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M: Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008, 14:6944-6954
7. Wang H, Wang H, Shen W, Huang H, Hu L, Ramdas L, Zhou YH, Liao WS, Fuller GN, Zhang W: Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 2003, 63:4315-4321 (Pubitemid 36950996)
8. Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H: Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep 2005, 13:341-345
9. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME: Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003, 63:3575-3584 (Pubitemid 36793038)
10. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, Zhang W: Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005, 4:7 (Pubitemid 40230559)
11. Hoeflich A, Fettscher O, Lahm H, Blum WF, Kolb HJ, Engelhardt D, Wolf E, Weber MM: Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res 2000, 60:834-838 (Pubitemid 30129510)
12. Diehl D, Hessel E, Oesterle D, Renner-Muller I, Elmlinger M, Langhammer M, Gottlicher M, Wolf E, Lahm H, Hoeflich A: IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer 2009, 124:2220-2225
13. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W: Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA: 2007, 104:11736-11741 (Pubitemid 47175082)
14. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E: Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001, 61:8601-8610
15. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W: Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 1999, 59:4228-4232 (Pubitemid 29418733)
16. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993, 77:229-233 (Pubitemid 23206808)
17. Lee DY, Kim SJ, Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999, 14:401-404
18. Yazawa T, Sato H, Shimoyamada H, Okudela K, Woo T, Tajiri M, Ogura T, Ogawa N, Suzuki T, Mitsui H, Ishii J, Miyata C, Sakaeda M, Goto K, Kashiwagi K, Masuda M, Takahashi T, Kitamura H: Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol 2009, 175:976-987
19. Sato H, Yazawa T, Suzuki T, Shimoyamada H, Okudela K, Ikeda M, Hamada K, Yamada-Okabe H, Yao M, Kubota Y, Takahashi T, Kamma H, Kitamura H: Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. Am J Pathol 2006, 169:1550-1566 (Pubitemid 351181988)
20. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G: Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994, 57:491-497
21. Karasik A, Menczer J, Pariente C, Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994, 78:271-276 (Pubitemid 24061738)
22. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y: Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998, 83:1713-1720 (Pubitemid 28501047)
23. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, Stalsberg H: Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005, 58:361-366 (Pubitemid 40516165)
24. Mohnike KL, Kluba U, Mittler U, Aumann V, Vorwerk P, Blum WF: Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr 1996, 155:81-86 (Pubitemid 126422135)
25. DeGraff DJ, Aguiar AA, Sikes RA: Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 2009, 1:115-130
26. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008, 68:8547-8554
27. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H: Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 2007, 282:18634-18644 (Pubitemid 47100243)
28. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997, 18:801-831 (Pubitemid 28009568)
29. Kaaks R, Lukanova A: Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001, 60:91-106 (Pubitemid 32183103)
30. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL: Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007, 104:5563-5568 (Pubitemid 47175720)
31. Blum WF, Horn N, Kratzsch J, Jorgensen JO, Juul A, Teale D, Mohnike K, Ranke MB: Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regul 1993, 3:100-104
32. Reeve JG, Morgan J, Schwander J, Bleehen NM: Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 1993, 53:4680-4685 (Pubitemid 23304400)
33. Grimberg A, Coleman CM, Shi Z, Burns TF, MacLachlan TK, Wang W, El-Deiry WS: Insulin-like growth factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther 2006, 5:1408-1414 (Pubitemid 44772270)
34. Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Haley NJ, Shore RE, Riboli E, Rinaldi S, Kaaks R: A prospective study of insulin-like growth factor-I. IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 2001, 92:888-892 (Pubitemid 32467380)
35. Kuang Z, Yao S, Keizer DW, Wang CC, Bach LA, Forbes BE, Wallace JC, Norton RS: Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factor-binding protein-2 (IGFBP-2). J Mol Biol 2006, 364:690-704 (Pubitemid 44755318)
36. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P: Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 2003, 105:14-19 (Pubitemid 36418479)
37. Baron-Hay S, Boyle F, Ferrier A, Scott C: Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004, 10:1796-1806 (Pubitemid 38435571)
38. Vorwerk P, Mohnike K, Wex H, Rohl FW, Zimmermann M, Blum WF, Mittler U: Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab 2005, 90:3022-3027 (Pubitemid 40686359)
39. Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS: Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res 2006, 16:224-239 (Pubitemid 44296071)
40. Miyoshi N, Naniwa K, Kumagai T, Uchida K, Osawa T, Nakamura Y: Alpha-tocopherol-mediated caspase-3 up-regulation enhances susceptibility to apoptotic stimuli. Biochem Biophys Res Commun 2005, 334:466-473 (Pubitemid 40982390)
41. Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD: Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001, 61:348-354 (Pubitemid 32095737)
42. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dorken B, Daniel PT: Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 2001, 20:2749-2760 (Pubitemid 32549832)
43. Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR: Immunohistochemical markers associated with brain metastases in patients with non-small-cell lung carcinoma. Cancer 2008, 113:2129-2138
44. Yoo J, Jung JH, Lee MA, Seo KJ, Shim BY, Kim SH, Cho DG, Ahn MI, Kim CH, Cho KD, Kang SJ, Kim HK: Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007, 22:318-325
45. Koomagi R, Volm M: Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. Anticancer Res 2000, 20:493-496 (Pubitemid 30189707)
46. Sudhakar C, Jain N, Swarup G: Sp1-like sequences mediate human caspase-3 promoter activation by p73 and cisplatin. Febs J 2008, 275:2200-2213 (Pubitemid 351569559)
47. Kutoh E, Margot JB, Schwander J: Identification and characterization of the putative retinoblastoma control element of the rat insulin-like growth factor binding protein-2 gene. Cancer Lett 1999, 136:187-194 (Pubitemid 29167184)
48. Torres J, Rodriguez J, Myers MP, Valiente M, Graves JD, Tonks NK, Pulido R: Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem 2003, 278:30652-30660 (Pubitemid 36994570)
49. Kuranaga E, Miura M: Nonapoptotic functions of caspases: caspases as regulatory molecules for immunity and cell-fate determination. Trends Cell Biol 2007, 17:135-144 (Pubitemid 46341825)
50. Nhan TQ, Liles WC, Schwartz SM: Physiological functions of caspases beyond cell death. Am J Pathol 2006, 169:729-737 (Pubitemid 44411940)
51. Butt AJ, Dickson KA, McDougall F, Baxter RC: Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 2003, 278:29676-29685 (Pubitemid 36962353)
52. Yin P, Xu Q, Duan C: Paradoxical actions of endogenous and exogenous insulin-like growth factor-binding protein-5 revealed by RNA interference analysis. J Biol Chem 2004, 279:32660-32666 (Pubitemid 39014724)
53. Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B, Wiench M, Hong J, Rechler MM: Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem 2006, 281:24588-24601 (Pubitemid 44274233)
54. Butt AJ, Fraley KA, Firth SM, Baxter RC: IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. Endocrinology 2002, 143:2693-2699
55. Nickerson T, Huynh H, Pollak M: Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 1997, 237:690-693 (Pubitemid 27434749)
56. Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997, 272:12181-12188 (Pubitemid 27202802)
57. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996, 81:411-420
58. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997, 82:2308-2313 (Pubitemid 27287605)
59. Fottner C, Sattarova S, Hoffmann K, Spottl G, Weber MM: Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin. Eur J Endocrinol 2008, 159:317-327
60. Besnard V, Corroyer S, Trugnan G, Chadelat K, Nabeyrat E, Cazals V, Clement A: Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim Biophys Acta 2001, 1538:47-58 (Pubitemid 32112771)
61. Berg U, Bang P, Carlsson-Skwirut C: Calpain proteolysis of insulin-like growth factor binding protein (IGFBP) -2 and -3, but not of IGFBP-1. Biol Chem 2007, 388:859-863 (Pubitemid 47184847)
62. Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A: Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 2005, 333:1011-1016 (Pubitemid 40854257)
63. DeGraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DR, Cohen P, Sikes RA: Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. J Cell Physiol 2007, 213:261-268 (Pubitemid 47378815)
64. Russo VC, Rekaris G, Baker NL, Bach LA, Werther GA: Basic fibroblast growth factor induces proteolysis of secreted and cell membrane-associated insulin-like growth factor binding protein-2 in human neuroblastoma cells. Endocrinology 1999, 140:3082-3090 (Pubitemid 30650622)
65. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008, 8:393-412
66. Martin JL, Baxter RC: Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 2007, 148:2532-2541